Abida Khan

1.4k total citations
81 papers, 970 citations indexed

About

Abida Khan is a scholar working on Molecular Biology, Organic Chemistry and Infectious Diseases. According to data from OpenAlex, Abida Khan has authored 81 papers receiving a total of 970 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 14 papers in Organic Chemistry and 11 papers in Infectious Diseases. Recurrent topics in Abida Khan's work include Synthesis and biological activity (10 papers), Computational Drug Discovery Methods (7 papers) and Cancer-related molecular mechanisms research (6 papers). Abida Khan is often cited by papers focused on Synthesis and biological activity (10 papers), Computational Drug Discovery Methods (7 papers) and Cancer-related molecular mechanisms research (6 papers). Abida Khan collaborates with scholars based in Saudi Arabia, India and Pakistan. Abida Khan's co-authors include Mohd Imran, Hamdy Khamees Thabet, Syed Mohammed Basheeruddin Asdaq, Ahmed Subeh Alshrari, Saleh I. Alaqel, Mohammed Kanan Alshammari, Mehnaz Kamal, Anil Kumar Nain, Shah Alam Khan and Md Tauquir Alam and has published in prestigious journals such as SHILAP Revista de lepidopterología, Brain Research and Molecules.

In The Last Decade

Abida Khan

72 papers receiving 940 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Abida Khan Saudi Arabia 19 267 218 191 105 93 81 970
Parameswaran Saravanan India 19 306 1.1× 232 1.1× 204 1.1× 185 1.8× 58 0.6× 56 945
Mohammad Z. Ahmed Saudi Arabia 17 349 1.3× 219 1.0× 91 0.5× 31 0.3× 102 1.1× 86 940
María Luisa Serrano Venezuela 14 186 0.7× 107 0.5× 279 1.5× 64 0.6× 36 0.4× 32 746
Anupam Nath Jha India 20 501 1.9× 165 0.8× 54 0.3× 85 0.8× 130 1.4× 56 1.1k
Ajamaluddin Malik Saudi Arabia 21 690 2.6× 196 0.9× 62 0.3× 39 0.4× 39 0.4× 103 1.4k
Bodee Nutho Thailand 13 187 0.7× 107 0.5× 159 0.8× 43 0.4× 31 0.3× 47 579
Sándor Gǒrög Hungary 22 333 1.2× 183 0.8× 110 0.6× 84 0.8× 214 2.3× 87 1.7k
Edeildo Ferreira da Silva‐Júnior Brazil 23 451 1.7× 391 1.8× 126 0.7× 198 1.9× 34 0.4× 93 1.3k
Vladimı́r Kubı́ček Czechia 14 189 0.7× 197 0.9× 45 0.2× 17 0.2× 33 0.4× 44 552
Kamlesh Kumari India 13 165 0.6× 196 0.9× 76 0.4× 15 0.1× 27 0.3× 74 718

Countries citing papers authored by Abida Khan

Since Specialization
Citations

This map shows the geographic impact of Abida Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abida Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abida Khan more than expected).

Fields of papers citing papers by Abida Khan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abida Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abida Khan. The network helps show where Abida Khan may publish in the future.

Co-authorship network of co-authors of Abida Khan

This figure shows the co-authorship network connecting the top 25 collaborators of Abida Khan. A scholar is included among the top collaborators of Abida Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abida Khan. Abida Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Khan, Muhammad Umer, et al.. (2025). Therapeutic Insights Into Alkanna tinctoria Phytochemicals as Cholinesterase Inhibitor for Alzheimer's Disease. Chemistry & Biodiversity. 22(6). 1 indexed citations
2.
Alhowail, Ahmad, et al.. (2025). Safety and efficacy of tocilizumab in COVID-19: A systematic evaluation of adverse effects and therapeutic outcomes. Journal of Infection and Public Health. 18(10). 102873–102873.
3.
4.
Thabet, Hamdy Khamees, Moustafa S. Abusaif, Mohd Imran, et al.. (2024). Discovery of novel 6-(piperidin-1-ylsulfonyl)-2H-chromenes targeting α-glucosidase, α-amylase, and PPAR-γ: Design, synthesis, virtual screening, and anti-diabetic activity for type 2 diabetes mellitus. Computational Biology and Chemistry. 111. 108097–108097. 22 indexed citations
5.
Thapa, Riya, Asif Ahmad Bhat, Moyad Shahwan, et al.. (2024). Proteostasis disruption and senescence in Alzheimer’s disease pathways to neurodegeneration. Brain Research. 1845. 149202–149202. 16 indexed citations
6.
Imran, Mohd, Abida Khan, Muhammad Irfan Siddique, et al.. (2024). Beyond the genome: MALAT1's role in advancing urologic cancer care. Pathology - Research and Practice. 256. 155226–155226. 2 indexed citations
7.
Imran, Mohd, Abida Khan, Nawaf Alotaibi, et al.. (2023). QcrB inhibition as a potential approach for the treatment of tuberculosis: A review of recent developments, patents, and future directions. Journal of Infection and Public Health. 16(6). 928–937. 5 indexed citations
8.
Alshammari, Mohammed Kanan, et al.. (2023). Nano-Enabled Strategies for the Treatment of Lung Cancer: Potential Bottlenecks and Future Perspectives. Biomedicines. 11(2). 473–473. 18 indexed citations
9.
Sarfraz, Muhammad, Mosab Arafat, Muhammad Irfan Siddique, et al.. (2023). Resveratrol-Laden Nano-Systems in the Cancer Environment: Views and Reviews. Cancers. 15(18). 4499–4499. 21 indexed citations
10.
Sarfraz, Muhammad, Abida Khan, Gaber El‐Saber Batiha, et al.. (2023). Nanotechnology-Based Drug Delivery Approaches of Mangiferin: Promises, Reality and Challenges in Cancer Chemotherapy. Cancers. 15(16). 4194–4194. 9 indexed citations
11.
Hudu, Shuaibu Abdullahi, Mazen Almehmadi, Ahad Amer Alsaiari, et al.. (2023). Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDA-Approved Treatment for Rare Pediatric Unmet Medical Need. Journal of Clinical Medicine. 12(15). 5114–5114. 17 indexed citations
12.
Imran, Mohd, Mohammed Kanan Alshammari, Mandeep Kumar Arora, et al.. (2023). Oral Brincidofovir Therapy for Monkeypox Outbreak: A Focused Review on the Therapeutic Potential, Clinical Studies, Patent Literature, and Prospects. Biomedicines. 11(2). 278–278. 19 indexed citations
13.
Imran, Mohd, et al.. (2022). Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 2021. Expert Opinion on Therapeutic Patents. 32(5). 591–604. 15 indexed citations
14.
Imran, Mohd, Ahmed Subeh Alshrari, Hamdy Khamees Thabet, Abida Khan, & Md. Afroz Bakht. (2021). Synthetic molecules as DprE1 inhibitors: A patent review. Expert Opinion on Therapeutic Patents. 31(8). 759–772. 36 indexed citations
15.
Imran, Mohd, Mandeep Kumar Arora, Syed Mohammed Basheeruddin Asdaq, et al.. (2021). Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. Molecules. 26(19). 5795–5795. 137 indexed citations
16.
Imran, Mohd, Syed Mohammed Basheeruddin Asdaq, Shah Alam Khan, et al.. (2021). Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades. Pharmaceuticals. 14(8). 710–710. 30 indexed citations
17.
Khan, Abida, et al.. (2020). Synthesis of novel N‐substitutedphenyl‐6‐oxo‐3‐phenylpyridazine derivatives as cyclooxygenase‐2 inhibitors. Drug Development Research. 81(5). 573–584. 12 indexed citations
18.
Khan, Abida, et al.. (2020). Discovery of Novel Pyridazine-Based Cyclooxygenase-2 Inhibitors with a Promising Gastric Safety Profile. Molecules. 25(9). 2002–2002. 23 indexed citations
19.
20.
Khan, Abida, et al.. (2019). Synthesis of some pyridazine derivatives as antioxidants and antimicrobial agents. Tropical Journal of Pharmaceutical Research. 18(12). 2633–2641. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Parameswaran Saravanan Breakdown of academic impact, for papers by Mohammad Z. Ahmed Breakdown of academic impact, for papers by María Luisa Serrano Breakdown of academic impact, for papers by Anupam Nath Jha Breakdown of academic impact, for papers by Ajamaluddin Malik Breakdown of academic impact, for papers by Bodee Nutho Breakdown of academic impact, for papers by Sándor Gǒrög Breakdown of academic impact, for papers by Edeildo Ferreira da Silva‐Júnior Breakdown of academic impact, for papers by Vladimı́r Kubı́ček Breakdown of academic impact, for papers by Kamlesh Kumari
Rankless by CCL
2026